Unaudited Financial Results for the half year ended September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr Lalchandani Labs reported its H1 FY26 (April–September 2025) results on November 14, 2025. Revenue from operations stood at ₹205.10 lacs, down from ₹212.54 lacs in H1 FY25, a decline of about 3.5%. However, total income rose to ₹234.40 lacs due to ₹29.30 lacs in other income. Profit after tax improved to ₹19.50 lacs from ₹15.19 lacs in the prior-year period, lifting EPS to ₹0.45 from ₹0.35. Cash from operations turned negative at ₹(13.12) lacs versus a positive ₹44.30 lacs for the full prior year. The auditor issued a qualified review report, flagging unpaid term loan installments (interest/penal interest not captured), non-provision of gratuity and leave encashment liabilities, and irregular deposits of statutory dues such as ESI, EPF, and TDS.
Profit growth looks positive on the surface, but the qualified audit opinion, negative operating cash flow, and unsettled loan dues signal underlying financial stress and governance concerns that shareholders should weigh carefully.